Stem cell transplantation

Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Flow chart of the study.
Fig. 2: Outcomes of transplanted and non-transplanted patients.

References

  1. 1.

    Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, del Cañizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–64.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

    PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. JCO. 2018;36:2684–92.

    CAS  Article  Google Scholar 

  4. 4.

    DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130:1156–64.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389–430.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109:1395–400.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Mawad R, Gooley TA, Sandhu V, Lionberger J, Scott B, Sandmaier BM, et al. Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. JCO. 2013;31:3883–8.

    Article  Google Scholar 

  9. 9.

    Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306:1874.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. JCO. 2013;31:2662–70.

    Article  Google Scholar 

  11. 11.

    McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng G-S, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-7 versus 2013-7 cohorts. Ann Intern Med. 2020;172:229.

    PubMed  Article  Google Scholar 

  12. 12.

    Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3:35–44.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Juliusson G, Hagberg O, Lazarevic VL, Ölander E, Antunovic P, Cammenga J, et al. Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood. 2019;134:1558–61.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Ustun C, Le-Rademacher J, Wang H-L, Othus M, Sun Z, Major B, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019;33:2599–609.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Deeg HJ, Steuten LM. Therapy for hematologic cancers in older patients, quality of life, and health economics: difficult decisions. JAMA Oncol. 2015;1:571.

    PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

GS, LA, and ER designed the study. AM and ASG collected the data and performed the statistical analysis. ASG and GS interpreted the data and wrote the first draft of the paper. ER, MR, DM, AX, FSDF, MS, EL, RI, CF, HD, PF, RPL, LA and GS were in charge of the patients. All authors contributed to data interpretation, paper writing, and critical review.

Corresponding author

Correspondence to G. Socié.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Del Galy, A.S., Marouf, A., Raffoux, E. et al. Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. Leukemia (2020). https://doi.org/10.1038/s41375-020-1004-9

Download citation